2H), 7.36 (s, 1H), 4.38 (d, J = 5.7 Hz, 2H), 4.26 - 4.18 (m, 4H), 3.42 - 3.35 (m, 2H), 3.21 - 3.12 (m, 2H), 2.14 - 2.02 (m, 2H), 1.92 - 1.83 (m, 2H), 1.72 - 1.61 (m, 2H), 1.42 - 1.33 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H) ppm. MS: M/e 457 $(M+1)^+$.

[0352] Compound A31: 7-(4-(3-aminopropoxy)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine

[0353] Step A: tert-butyl (3-(4-formylphenoxy)propyl)carbamate

[0354] To a solution of 4-hydroxybenzaldehyde (1.22 g, 10 mmol), tert-butyl (3-hydroxypropyl)carbamate (2.62 g, 15 mmol) and PPh_3 (3.93 g, 15 mmol) in THF (15 mL) was added DIAD (7.57 g, 15 mmol, 40% in toluene solution) dropwise. Then the mixture was stirred at room temperature for 5 hours. The mixture was diluted with water (50 mL), extracted with EtOAc (60 mL x 2). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered, concentrated and the residue was purified by combi flash to give the target compound (2.53 g, 90%). MS: M/e 224 $(M+H - t\text{-}Bu)^+$.

[0355] Step B: tert-butyl(3-(4-((4-(bis(4-methoxybenzyl)amino)-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)phenoxy)propyl)carbamate

[0356] To a solution of 7-bromo-2-butoxy-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.57 mmol) in THF (8 mL) was added a solution of n-BuLi (0.9 mL, 1.42 mmol) dropwise and maintaining the temperature between -75 ~ -65°C. After 1 h, a mixture of the product of Step A (238 mg, 0.855 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70°C for 0.5 h and then warmed to room temperature for 2 hours. The reaction was quenched with saturated NH_4Cl solution, extracted with EtOAc (50 mL), washed with brine, dried over Na_2SO_4, filtered, and concentrated. The residue was purified by *prep*-TLC (EA/PE = 1/3) to give the target compound (100 mg, crude). MS: M/e 727 $(M+1)^+$.

[0357] Step C: 7-(4-(3-aminopropoxy)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine **(Compound A31)**

[0358] To a mixture of the product of Step B (100 mg, crude) in TFA (3 mL) was added Et_3SiH (1 mL). The reaction was heated at 85°C overnight. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (3 mL) and the resulting mixture was heated at 85°C overnight. The mixture was concentrated to dryness and the residue was purified by *prep*-HPLC. The collected fraction was basified with $NaHCO_3$ solution, extracted with DCM (50 mL x 2), washed with brine, dried over Na_2SO_4, filtered, and concentrated to give the target compound (30 mg, 15% for two steps). ^{1}HNMR (400 MHz, DMSO-d_6) δ 8.11 (s, 1H), 8.02 (s, 1H), 7.25 (s, 1H), 7.20 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 4.20 (t, J = 6.0 Hz, 2H), 4.05 (s, 2H), 3.97 (t, J = 6.4 Hz, 2H), 3.05 – 2.90 (m, 2H), 2.68 (t, J = 7.2 Hz, 2H), 1.86 – 1.59(m, 4H), 1.49 – 1.35 (m, 2H), 0.92 (t, J = 7.6 Hz, 3H) ppm. MS: M/e 371 $(M+1)^+$.

[0359] Compound A32: 2-butoxy-7-((6-(3-(dimethylamino)propoxy)pyridine-3-yl) methyl)imidazo[2,1-f][1,2,4]triazin-4-amine

[0360] Step A: 6-(3-(dimethylamino)propoxy)nicotinaldehyde

[0361] DEAD (2.1 g, 12 mmol) was added dropwise to a solution of 6-hydroxy nicotin aldehyde (1 g, 8.1 mmol), 3-(dimethylamino)propan-1-ol (837 mg, 8.1 mmol) and triphenylphosphane (3.1

Claims:

1. A compound of Formula (I),



(I)

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein

X is N;

L^1 is $-(CR^aR^b)_m-$, -O-, -S-, -S(O)-, $-SO_2-$, -C(O)-, -C(O)O-, -OC(O)-, $-NR^a-$, $-C(O)NR^a-$, $-NR^aC(O)-$, $-NR^aC(O)O-$, $-NR^aC(O)NR^b-$, $-SO_2NR^a-$, $-NR^aSO_2-$, $-NR^aS(O)_2NR^b-$, $-NR^aS(O)NR^b-$, $-C(O)NR^aSO_2-$, $-C(O)NR^aSO-$, or $-C(=NR^a)NR^b-$,

wherein m is a number of 1 to 8, and one or two CR^aR^b moieties in $-(CR^aR^b)_m-$ are unreplaced or replaced with one or more moieties selected from O, S, SO, SO_2, C(O) and NR^a;

R^a and R^b, at each occurrence, are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, or $-OR^c$;

wherein R^c is hydrogen, alkyl, alkoxy-alkyl-, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl;

R^1 is $-OR^{1a}$, $-SR^{1a}$, $-NR^{1a}R^{1b}$, $-COR^{1a}$, $-SO_2R^{1a}$, $-C(=O)OR^{1a}$, $-C(=O)NR^{1a}R^{1b}$, $-C(=NR^{1a})NR^{1b}R^{1c}$, $-N(R^{1a})C(=O)R^{1b}$, $-N(R^{1a})C(=O)OR^{1b}$, $-N(R^{1a})C(O)NR^{1b}R^{1c}$, $-N(R^{1a})S(O)NR^{1b}R^{1c}$, $-N(R^{1a})S(O)_2NR^{1b}R^{1c}$, $-NR^{1a}SO_2R^{1b}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{1d};

R^{1a}, R^{1b}, and R^{1c} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or two or three substituents selected from halogen, $-C_{1-8}$alkyl optionally substituted with R^{1e}, cycloalkyl optionally substituted with R^{1e}, heterocyclyl optionally substituted with R^{1e}, aryl optionally substituted with R^{1e}, heteroaryl optionally substituted with R^{1e}, $CH_3-(OCH_2CH_2)_n-$ (wherein n is a number of 3 to 10) or $-OR^{1f}$;

wherein R^{1e} is halogen, nitro, cyano, hydroxy, amino ($-NH_2$), alkylamino, dialkylamino, or $-C_{1-6}$alkyl optionally substituted with halogen;

wherein R^{1f} is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with $-C_{1-4}$alkyl or halogen;

R^{1d}, at each occurrence, is independently hydrogen, oxo, -CN, $-NO_2$, amino ($-NH_2$), alkylamino, dialkylamino, halogen, haloalkyl, alkyl, haloalkoxy, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl;

R^2 and R^3, at each occurrence, are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl,

alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1-3 substituents selected from oxo, -CN, $-NO_2$, amino ($-NH_2$), alkylamino, dialkylamino, halogen, hydroxy, haloalkyl, alkyl, haloalkoxy, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl;

R^4 is hydrogen, halogen, cyano, $-NO_2$, $-OR^{4a}$, $-SR^{4a}$, $-NR^{4a}R^{4b}$, $-COR^{4a}$, $-SO_2R^{4a}$, $-C(=O)OR^{4a}$, $-C(=O)NR^{4a}R^{4b}$, $-C(=NR^{4a})NR^{4b}R^{4c}$, $-N(R^{4a})C(=O)R^{4b}$, $-N(R^{4a})C(=O)OR^{4b}$, $-N(R^{4a})C(O)NR^{4b}R^{4c}$, $-N(R^{4a})S(O)NR^{4b}R^{4c}$, $-N(R^{4a})S(O)_2NR^{4b}R^{4c}$, $-NR^{4a}SO_2R^{4b}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{4d};

R^{4a}, R^{4b}, and R^{4c} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, NH_2-, alkylamino, dialkylamino or alkoxy;

R^{4d}, at each occurrence, is independently hydrogen, oxo, -CN, $-NO_2$, halogen, NH_2-, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, NH_2-, alkylamino, dialkylamino or alkoxy;

Ring A is aryl or heteroaryl;

R^5 is halogen, hydroxy, alkyl, haloalkyl, alkoxy, haloalkoxy, -oxo-, or $-C(=O)OR^{5a}$, wherein R^{5a} is hydrogen, alkyl, or haloalkyl;

p is a number of 0, 1, 2 or 3;

L^2 is a direct bond, $-(CR^fR^g)_t-$, -O-, -S-, -S(O)-, $-SO_2-$, -C(O)-, -C(O)O-, -OC(O)-, or $-NR^d-$, wherein R^d is $-C_{1-6}$alkyl, wherein t is a number of 1 to 8, and one or two CR^fR^g moieties in $-(CR^fR^g)_t-$ are un-replaced or replaced with one or more moieties selected from O, S, SO, SO_2, C(O) and NR^f;

R^f and R^g, at each occurrence, are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl;

R^6 is $-NR^{6a}R^{6b}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{6c};

R^{6a} and R^{6b}, are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, NH_2-, alkylamino, dialkylamino or alkoxy;

R^{6c} is independently hydrogen, halogen, cyano, $-NO_2$, $-OR^{6d}$, $-SR^{6d}$, $-NR^{6d}R^{6e}$, $-COR^{6d}$, $-SO_2R^{6d}$, $-C(=O)OR^{6d}$, $-C(=O)NR^{6d}R^{6e}$, $-C(=NR^{6d})NR^{6e}R^{6f}$, $-N(R^{6d})C(=O)R^{6e}$, $-N(R^{6d})C(=O)OR^{6e}$, $-N(R^{6d})C(O)NR^{6e}R^{6f}$, $-N(R^{6d})S(O)NR^{6e}R^{6f}$, $-N(R^{6d})S(O)_2NR^{6e}R^{6f}$, -

$NR^{6d}SO_2R^{6e}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{6g};

R^{6d}, R^{6e} and R^{6f}, are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or two or three substituents R^{6g};

R^{6g}, at each occurrence, is independently hydrogen, halogen, cyano, $-NO_2$, $-OR^{6h}$, $-SR^{6h}$, $-NR^{6h}R^{6i}$, $-COR^{6h}$, $-SO_2R^{6h}$, $-C(=O)OR^{6h}$, $-C(=O)NR^{6h}R^{6i}$, $-C(=NR^{6h})NR^{6i}R^{6j}$, $-N(R^{6h})C(=O)R^{6i}$, $-N(R^{6h})C(=O)OR^{6i}$, $-N(R^{6h})C(O)NR^{6i}R^{6j}$, $-N(R^{6h})S(O)NR^{6i}R^{6j}$, $-N(R^{6h})S(O)_2NR^{6i}R^{6h}$, $-NR^{6h}SO_2R^{6i}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl,

R^{6h}, R^{6i} and R^{6j}, are independently hydrogen, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl or heteroaryl is independently and optionally substituted with one or two or three substituents selected from halogen, $-C_{1-4}$alkyl, $-C_{1-4}$alkoxy, hydroxy, nitro, $-NH_2$, alkylamino, dialkylamino, or cyano.

2. The compound according to Claim 1, wherein R^1 is $-OR^{1a}$, or $-NR^{1a}R^{1b}$; wherein R^{1a}, R^{1b}, are independently hydrogen, $-C_{1-8}$alkyl, or $-C_{2-8}$alkenyl, each of said $-C_{1-8}$alkyl is optionally substituted with one or two or three substituents selected from heterocyclyl optionally substituted with R^{1e}, aryl optionally substituted with R^{1e}, $CH_3-(OCH_2CH_2)_n-$ (wherein n is a number of 3 to 10), or $-OR^{1f}$;

wherein R^{1e} is halogen, or $-C_{1-6}$alkyl optionally substituted with halogen;

wherein R^{1f} is $-C_{1-8}$alkyl, aryl, or heteroaryl, each of which is optionally substituted with $-C_{1-4}$alkyl or halogen.

3. The compound according to Claim 1, wherein R^1 is $-OR^{1a}$, wherein R^{1a} is $-C_{1-8}$alkyl optionally substituted with one or two or three substituents selected from halogen, $-C_{1-8}$alkyl optionally substituted with R^{1e}, cycloalkyl optionally substituted with R^{1e}, heterocyclyl optionally substituted with R^{1e}, aryl optionally substituted with R^{1e}, heteroaryl optionally substituted with R^{1e}, $CH_3-(OCH_2CH_2)_n-$ (wherein n is a number of 3 to 10), or $-OR^{1f}$, wherein R^{1e} and R^{1f} are as defined in Claim 1.

4. The compound according to Claim 1, wherein R^1 is $-OR^{1a}$ or $-NHR^{1a}$, wherein R^{1a} is a branched $-C_{4-8}$alkyl wherein the branched substituent is at the alpha position with respect to the oxygen atom.

5. The compound according to Claim 1, wherein R^1 is $-OR^{1a}$ or $-NHR^{1a}$, wherein R^{1a} is butan-2-yl, pentan-2-yl, pentan-3-yl, heptan-2-yl, heptan-3-yl, heptan-4-yl, octan-2-yl, octan-3-yl, octan-4-yl, or octan-5-yl.

6. The compound according to any one of Claims 1-5, wherein R^5 is halogen, hydroxy, $-C_{1-8}$alkyl, -haloC_{1-8}alkyl, $-C_{1-8}$alkoxy, -haloC_{1-8}alkoxy, or $-C(=O)OR^{5a}$, wherein R^{5a} is hydrogen, $-C_{1-}$

$_8$alkyl, or -haloC_{1-8}alkyl; and p is a number of 0, 1, or 2.

7. The compound according to any one of Claims 1-6, wherein Ring A is phenyl or 5- to 8-membered heteroaryl comprising one or two or three heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur as ring members.

8. The compound according to any one of Claims 1-7, wherein L^2 is a direct bond, $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, -O-, or $-NR^d-$, wherein R^d is $-C_{1-6}$alkyl.

9. The compound according to any one of Claims 1-8, wherein R^6 is $-NR^{6a}R^{6b}$, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, -cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of said $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, -cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{6c};

R^{6a} and R^{6b}, are independently hydrogen or $-C_{1-8}$alkyl;

R^{6c} is independently hydrogen, halogen, $-OR^{6d}$, $-SR^{6d}$, $-NR^{6d}R^{6e}$, $-COR^{6d}$, $-SO_2R^{6d}$, $-C(=O)NR^{6d}R^{6e}$, or $-C_{1-8}$alkyl, said $-C_{1-8}$alkyl is independently and optionally substituted with one or two or three substituents R^{6g};

R^{6d} and R^{6e} are independently hydrogen, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, heterocyclyl, or aryl, each of said $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, heterocyclyl, or aryl is optionally substituted with one or two or three substituents R^{6g};

R^{6g}, at each occurrence, is independently hydrogen, halogen, $-OR^{6h}$, $-SR^{6h}$, $-NR^{6h}R^{6i}$, $-N(R^{6h})C(=O)OR^{6i}$, $-C_{1-8}$alkyl, heterocyclyl, aryl, or heteroaryl, wherein R^{6h} and R^{6i}, are independently hydrogen or $-C_{1-8}$alkyl.

10. The compound according to Claim 9, wherein L^2-R^6 is selected from:

a) L^2 is $-CH_2-$ or $-CH_2CH_2-$, and R^6 is a 5-, 6-, 7- or 8-membered saturated monocyclic ring comprising one or two or three nitrogen heteroatoms as ring members or a bicyclic ring comprising one, two or three heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur as ring members, each of which is optionally substituted with one or two substituents R^{6c}, wherein R^{6c} is $-NR^{6d}R^{6e}$, $-COR^{6d}$, $-OR^{6d}$, or $-C_{1-8}$alkyl optionally substituted with hydroxy, wherein R^{6d} and R^{6e} are independently hydrogen or $-C_{1-8}$alkyl or phenyl, wherein said alkyl is optionally substituted with NH_2-, alkylamino, or dialkylamino;

b) L^2 is $-CH_2-$ or $-CH_2CH_2-$, and R^6 is R^6 is $-NR^{6a}R^{6b}$, wherein R^{6a} and R^{6b} are independently hydrogen or C_{1-8}alkyl;

c) L^2 is a direct bond and R^6 is $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, or $-C_{2-8}$alkynyl;

d) L^2 is -O-, and R^6 is $-C_{1-8}$alkyl or heterocyclyl, said $-C_{1-8}$alkyl and heterocyclyl optionally substituted with one or two R^{6c}, wherein R^{6c} is $-C_{1-8}$alkyl, $-NR^{6d}R^{6e}$ and $-COR^{6d}$, wherein R^{6d} and R^{6e} are independently $-C_{1-8}$alkyl optionally substituted with NH_2-, alkylamino, or dialkylamino;

e) L^2 is $-NR^d-$, wherein R^d is $-C_{1-6}$alkyl, and R^6 is $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, or $-C_{2-8}$alkynyl, each of which is optionally substituted with one or two R^{6c}, wherein R^{6c} is $-C_{1-8}$alkyl or $-NR^{6d}R^{6e}$, wherein R^{6d} and R^{6e} are independently $-C_{1-8}$alkyl; or

f) L^2 is a direct bond and R^6 is cycloalkyl, aryl, or heteroaryl, each of which is independently and optionally substituted with one or two or three substituents R^{6c}.

11. The compound according to Claim 10, wherein L^2 is $-CH_2-$ or $-CH_2CH_2-$, and R^6 is

pyrrolidinyl, piperidinyl, triazolyl, azepanyl, piperazinyl or morpholino or (1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl, each of which is further optionally substituted with one or two substituents R^{6c}, wherein R^{6c} is $-NR^{6d}R^{6e}$, $-COR^{6d}$, $-OR^{6d}$, or $-C_{1-8}$alkyl optionally substituted with hydroxy, wherein R^{6d} and R^{6e} are independently hydrogen or $-C_{1-8}$alkyl or phenyl, wherein said alkyl is optionally substituted with NH_2-, alkylamino, or dialkylamino.

12. The compound according to Claim 10, wherein L^2 is $-CH_2-$ or $-CH_2CH_2-$, and R^6 is pyrrolidin-1-yl, morpholino, piperidin-1-yl, 4-methylpiperazin-1-yl, piperazin-1-yl, piperidin-4-yl, 4-(2-(dimethylamino)acetyl)piperazin-1-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl, 4-aminopiperidin-1-yl, 3-(dimethylamino)pyrrolidin-1-yl, 4-phenoxypiperidin-1-yl, 1H-1,2,4-triazol-1-yl, 4-(3-hydroxypropyl)piperazin-1-yl, or piperidin-3-yl.

13. The compound according to Claim 10, wherein L^2-R^6 is selected from:

a) pyrrolidin-1-ylmethyl, morpholinomethyl, piperidin-1-ylmethyl, (4-methylpiperazin-1-yl)methyl, piperazin-1-ylmethyl, piperidin-4-ylmethyl, (4-(2-(dimethylamino)acetyl)piperazin-1-yl)methyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl, 2-(pyrrolidin-1-yl)ethyl, (4-aminopiperidin-1-yl)methyl, (3-(dimethylamino)pyrrolidin-1-yl)methyl, (4-phenoxypiperidin-1-yl)methyl, (1H-1,2,4-triazol-1-yl)methyl, (4-(3-hydroxypropyl)piperazin-1-yl)methyl, or piperidin-3-ylmethyl;

b) aminomethyl;

d) 3-(methylamino)propoxy, 3-(dimethylamino)propoxy, 3-(diethylamino)propoxy, 2-aminoethoxy, 3-(dimethylamino)-2,2-dimethylpropoxy, methoxy, 2-(methylamino)ethoxy, 2-(N-methylacetamido)ethoxy, 3-(piperidin-1-yl)propoxy, 3-morpholinopropoxy, 3-(pyrrolidin-1-yl)propoxy, 3-aminopropoxy, (1R,5S)-8-azabicyclo[3.2.1]octan-3-yloxy, piperidin-4-yloxy, (1R,5S)-8-ethyl-8-azabicyclo[3.2.1]octan-3-yloxy, 1-ethylpyrrolidin-3-yloxy, or pyrrolidin-3-yloxy; or

e) (2-(dimethylamino)ethyl)(methyl)amino.

14. The compound according to any one of Claims 1-7, wherein ring A is phenyl, and L^1 and L^2-R^6 are in para positions of the phenyl ring, and said phenyl ring is further optionally substituted with one R^5, wherein L^1, L^2, R^5 and R^6 are defined as in Claim 1 .

15. The compound according to any one of Claims 1-7, wherein ring A is pyridyl, and the methylene group and Het on the pyridyl ring are in para positions of the pyridyl ring, and L^1 and L^2-R^6 are in para positions of the pyridyl ring, and said pyridyl ring is further optionally substituted with one R^5, wherein L^1, L^2, R^5 and R^6 are defined as in Claim 1.

16. A compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, selected from:

Compound A1: 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A2: 2-butoxy-7-(4-(3-(dimethylamino)propoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A3: 2-butoxy-7-(4-(morpholinomethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A4: N^1-(5-((4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7- yl)methyl)pyridin-2-yl)-N^1,N^2,N^2-trimethylethane-1,2-diamine;

Compound A5: 2-butoxy-7-(4-(piperidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A6: 2-butoxy-7-(4-((4-methylpiperazin-1-yl)methyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A7: 2-butoxy-7-(3-(piperidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A8: 2-butoxy-7-((2-isopropyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A9: 2-butoxy-7-((2-isopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A10: 2-butoxy-7-(4-(piperazin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A11: 2-butoxy-7-(3-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A12: 2-butoxy-7-(3-(morpholinomethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A13: 2-butoxy-7-(3-((4-methylpiperazin-1-yl)methyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A14: 2-butoxy-7-(2-(morpholinomethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A15: 2-butoxy-7-(2-(piperidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A16: 2-isobutoxy-7-(3-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A17: 2-(2-methoxyethoxy)-7-(3-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine**;**

Compound A18: 7-(3-(pyrrolidin-1-ylmethyl)benzyl)-2-(4,4,4-trifluorobutoxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A19: 2-butoxy-7-(2-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A20: 2-butoxy-7-(2-fluoro-4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A21: 2-butoxy-7-(4-(3-(piperidin-1-yl)propoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A22: 2-butoxy-7-(4-(3-morpholinopropoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A23: 2-butoxy-7-(3-(3(dimethylamino)propoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A24: 2-butoxy-7-(3-(3-(dimethylamino)propoxy)-4-fluorobenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A25: 2-butoxy-7-((4'-(pyrrolidin-1-ylmethyl)-[1,1'-biphenyl]-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A26: 2-butoxy-7-(2-fluoro-5-(pyrrolidin-1-ylmethyl)benzyl)Imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A27: 2-butoxy-7-(2-fluoro-5-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A28: 2-butoxy-7-(4-(3-(pyrrolidin-1-yl)propoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A29: 2-butoxy-7-(4-(3-(diethylamino)propoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A30: 2-butoxy-7-((4'-(pyrrolidin-1-ylmethyl)-[1,1'-biphenyl]-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A31: 7-(4-(3-aminopropoxy)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A32: 2-butoxy-7-((6-(3-(dimethylamino)propoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A33: 2-butoxy-7-(4-(piperidin-4-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A34: 2-butoxy-7-((5-chloro-6-(3-(dimethylamino)propoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A35: 2-butoxy-7-(4-(3-(dimethylamino)propoxy)-3-fluorobenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A36: 2-butoxy-7-(4-(3-(dimethylamino)propoxy)-2-fluorobenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A37: 7-((6-(2-aminoethoxy)pyridin-3-yl)methyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A38: 7-(4-(((1R,5S)-8-azabicyclo[3.2.1]octan-3-yl)oxy)-2- fluorobenzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A39: 1-(4-(4-((4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)methyl)benzyl)piperazin-1-yl)-2-(dimethylamino)ethan-1-one;

Compound A40: 2-butoxy-7-((5-chloro-6-(piperidin-4-yloxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A41: 7-(4-(((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A42: 2-butoxy-7-(4-(2-(pyrrolidin-1-yl)ethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A43: 7-(4-((4-aminopiperidin-1-yl)methyl)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A44: 2-butoxy-7-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A45: 2-butoxy-7-((5-chloro-6-(3-(dimethylamino)-2,2-dimethylpropoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A46: 7-(4-(aminomethyl)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A47: 2-butoxy-7-(4-((4-phenoxypiperidin-1-yl)methyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A48: 2-((5-methylisoxazol-3-yl)methoxy)-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A49: 2-butoxy-7-(4-(((1R,5S)-8-ethyl-8-azabicyclo[3.2.1] octan-3-yl)oxy)-2-fluorobenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A50: 2-butoxy-7-((5-methoxypyridin-2-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A51: 2-butoxy-7-((6-methoxypyridin-2-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A52: 7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine;

Compound A53: 2-butoxy-7-((6-(3-(dimethylamino)-2,2-dimethylpropoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A54: 2-isobutoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A55: 2-butoxy-7-((3-methoxypyridin-2-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A56: (4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)(3-methoxypyridin-2-yl)methanol;

Compound A57: methyl 5-((4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-2-(3-(dimethylamino)propoxy)benzoate;

Compound A58: 2-butoxy-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A59: N-(2-((5-((4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)methyl)pyridin-2-yl)oxy)ethyl)-N-methylacetamide;

Compound A60: 2-butoxy-7-(4-((1-ethylpyrrolidin-3-yl)oxy)-2- fluoro benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A61: 2-butoxy-7-(2-fluoro-4-(pyrrolidin-3-yloxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A62: 7-(4-((1H-1,2,4-triazol-1-yl)methyl)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A63: 2-butoxy-7-(4-(3-(methylamino)propoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A64: N^2-(furan-2-ylmethyl)-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-

f][1,2,4]triazine-2,4-diamine;

Compound A65: 4-amino-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-2-ol;

Compound A66: 2-butoxy-7-(4-(1-methylpyrrolidin-3-yl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A67: N2-butyl-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine;

Compound A68: 2-(pyridin-3-ylmethoxy)-7-(4-(pyrrolidin-1-ylmethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A69: 7-(4-(pyrrolidin-1-ylmethyl)benzyl)-2-(4,4,4-trifluorobutoxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A70: 7-(3-(aminomethyl)benzyl)-2-butoxyimidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A71: 3-(4-(4-((4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)methyl)benzyl)piperazin-1-yl)propan-1-ol;

Compound A72: 2-butoxy-7-((5-methyl-6-(piperidin-4-yloxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A73: (4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)(4-methoxypyridin-2-yl)methanol;

Compound A74: (4-amino-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)(pyridin-2-yl)methanol;

Compound A75: 2-butoxy-7-(1-(4-(pyrrolidin-1-ylmethyl)phenyl)ethyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A76: 2-butoxy-7-((1-(piperidin-3-ylmethyl)-1H-pyrazol-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A77: 7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-2-(pentan-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A78: 7-((5-methyl-6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-2-(pentan-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A79: 3-((4-amino-7-((6-(2-(methylamino)ethoxy)pyridin-3 yl)methyl) imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A80: 7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-2-((tetrahydrofuran-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A81: (R or S) 3-((4-amino-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A82: (S or R) 3-((4-amino-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A83: 7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-2-(pentan-3-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A84: 2-(hexan-3-yloxy)-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A85: 3-((4-amino-7-(4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol.;

Compound A86: 3-((4-amino-7-((6-(3-(methylamino)propoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol.;

Compound A87: 2-(heptan-4-yloxy)-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A88: 7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-2-((tetrahydrofuran-2-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A89: (S)-2-(sec-butoxy)-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A90: (S)-7-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-2-(pentan-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A91: 3-((4-amino-7-(3-fluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A92: (R or S) 3-((4-amino-7-(4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A93: (S or R) 3-((4-amino-7-(4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol.;

Compound A94:3-((4-amino-7-(4-(methyl(2-(methylamino)ethyl)amino)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol**;**

Compound A95:3-((4-amino-7-(4-(2-(methylamino)ethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol**;**

Compound A96: 3-((4-amino-7-(4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol.;

Compound A97: 3-((4-amino-7-(2-fluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A98: 3-((4-amino-7-(3-methoxy-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol**;**

Compound A99: (S)-7-(3-fluoro-4-(2-(methylamino)ethoxy)benzyl)-2-(pentan-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine;

Compound A100: (S)-7-(4-(2-(methylamino)ethoxy)benzyl)-2-(pentan-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.;

Compound A101: (R or S)-3-((4-amino-7-(2-methoxy-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol**;**

Compound A102: 3-((4-amino-7-(3-chloro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A103: (R or S)-3-((4-amino-7-(3-methyl-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A104: (R or S)-3-((4-amino-7-(3-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A105: (R or S)-3-((4-amino-7-(3-fluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol**;**

Compound A106: (S or R)-3-((4-amino-7-(3-fluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol**;**

Compound A107: (R or S)-3-((4-amino-7-(2-methyl-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A108: (R or S)-3-((4-amino-7-(2-chloro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A109: (3R or S)-3-((4-amino-7-((6-((1-(methylamino)propan-2-yl)oxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A110: (R or S)-3-((4-amino-7-(4-(3-(methylamino)propyl)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A111: (R or S)-3-((4-amino-7-(2,3-difluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A112: (R or S)-3-((4-amino-7-(2,5-difluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A113: (R or S)-3-((4-amino-7-(2-methoxy-5-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A114: (R or S)-3-((4-amino-7-(3,5-difluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A115: (R or S)-3-((4-amino-7-(2-fluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A116: (R or S)-3-((4-amino-7-(3-methoxy-5-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A117: (R or S)-3-((4-amino-7-(4-methoxy-3-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A118: (R or S)-3-((4-amino-7-(2-methoxy-3-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A119: (R or S)-3-((4-amino-7-(4-(2-(methylamino)ethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A120: (S or R)-3-((4-amino-7-(4-(2-(methylamino)ethyl)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A121: (R or S)-3-((4-amino-7-(2-ethoxy-4-(2-(methylamino)ethoxy) benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol.;

Compound A122: (R or S)-3-((4-amino-7-((6-(2-(methylamino)propoxy)pyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol;

Compound A123: (R or S)-3-((4-amino-7-(2,6-difluoro-4-(2-(methylamino)ethoxy)benzyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol; or

Compound A124: (R or S)-3-((4-amino-7-((4-(2-(methylamino)ethoxy)naphthalen-1-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hexan-1-ol.

17. A pharmaceutical composition comprising the compound according to any one of Claims 1-16, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

18. A use of a compound according to any one of Claims 1-16, or a pharmaceutically acceptable salt thereof as a TLR7 agonist in the manufacture of a medicament for treating a disease or disorder.

19. The use according to claim 18, wherein the disease or disorder is cancer.

20. The use according to claim 18, wherein the disease or disorder is melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza.